Peroxisome Proliferator-Activated Receptors
Peroxisome Proliferator-Activated Receptors is a research topic within Molecular Biology. Science Explorer counts 35k research works in it since 1950. 21.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the Peroxisome Proliferator-Activated Receptors (PPARs), a group of nuclear receptors that play a crucial role in regulating metabolism, inflammation, lipid physiology, and various metabolic diseases such as obesity and diabetes. The cluster explores the diverse biology, mechanisms of action, and therapeutic implications of PPARs, including their involvement in transcriptional regulation and the role of fatty acid-binding proteins.
- Peroxisome Proliferator-Activated Receptors
- PPARs
- metabolism
- inflammation
- lipid
- nuclear receptors
- obesity
- diabetes
- fatty acid-binding proteins
- transcriptional regulation
- Research works
- 35k fractional, since 1950
- In the world top 10%
- 7.3k per year above
- Top-10% rate
- 21.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -9% the tick is no change
Which countries lead Peroxisome Proliferator-Activated Receptors research?
By volume, China and the United States publish the most (1.2k and 609 works in 2022–2025).
By volume, 2022–2025
- 1 China 1.2k works
- 2 United States 609 works
- 3 Japan 186 works
- 4 India 153 works
- 5 Germany 106 works
- 6 South Korea 99 works
- 7 Italy 70 works
- 8 France 66 works
- 9 United Kingdom 65 works
- 10 Canada 63 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Peroxisome Proliferator-Activated Receptors research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Peroxisome Proliferator-Activated Receptors research, followed by Yangzhou University and University of North Carolina at Chapel Hill.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 15 works
- 2 Yangzhou UniversityChina 11 works
- 3 University of North Carolina at Chapel HillUnited States 11 works
- 4 Sichuan UniversityChina 11 works
- 5 Sun Yat-sen UniversityChina 11 works
- 6 Peking UniversityChina 10 works
- 7 Zhejiang UniversityChina 10 works
- 8 Chongqing Medical UniversityChina 10 works
- 9 Shanghai Jiao Tong UniversityChina 10 works
- 10 Ministry of Agriculture and Rural AffairsChina 10 works
Who are the leading researchers in Peroxisome Proliferator-Activated Receptors?
The most-cited researchers publishing on Peroxisome Proliferator-Activated Receptors include Tien Yin Wong and Cornelia M. van Duijn.
- 1 Tien Yin Wong Singapore 4.3k citations
- 2 Cornelia M. van Duijn Netherlands 3.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Peroxisome Proliferator-Activated Receptors research done?
The largest centres of Peroxisome Proliferator-Activated Receptors research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Wuhan (China).
Where is the best place to study Peroxisome Proliferator-Activated Receptors?
Among universities, judged by research, Anhui Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College and Southern Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Anhui Medical UniversityChina | 63.8 | 29.1% | 9.1× | 9 | +61.6% |
| 2 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 62.6 | 33.0% | 4.7× | 15 | -20.8% |
| 3 | Southern Medical UniversityChina | 56.0 | 27.9% | 8.1× | 9 | +10.9% |
| 4 | Chongqing Medical UniversityChina | 55.1 | 26.4% | 9.6× | 10 | -27.9% |
| 5 | Zhejiang UniversityChina | 47.6 | 29.5% | 1.6× | 10 | +36.1% |
| 6 | Wuhan UniversityChina | 47.5 | 34.4% | 2.4× | 10 | +17.2% |
| 7 | Peking UniversityChina | 44.5 | 33.8% | 2.1× | 10 | -33.9% |
| 8 | Shanghai Jiao Tong UniversityChina | 44.0 | 33.2% | 1.4× | 10 | -2.1% |
| 9 | Harvard UniversityUnited States | 42.9 | 31.6% | 2.3× | 9 | -35.8% |
| 10 | Capital Medical UniversityChina | 42.3 | 22.1% | 5.1× | 10 | +18.5% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Peroxisome Proliferator-Activated Receptors research growing?
Output in 2018–2022 was 9% lower than in 2013–2017, peaking in 2008.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.